Cyclacel Pharmaceuticals, Inc. (CYCCP)
| Previous close | 12.65 |
| Open | 12.86 |
| Bid | 9.00 x 100 |
| Ask | 0.00 x 0 |
| Day's range | 7.60 - 12.86 |
| 52-week range | 5.25 - 22.20 |
| Volume | |
| Avg. volume | 1,437 |
| Market cap | 15.231M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.60 (7.49%) |
| Ex-dividend date | 19 Jan 2024 |
| 1y target est | N/A |
- Simply Wall St.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future
Cyclacel Pharmaceuticals, Inc. ( NASDAQ:CYCC ) is possibly approaching a major achievement in its business, so we would...
- Insider Monkey
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript March 19, 2024 Cyclacel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-6.23, expectations were $-6.35. CYCC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the […]
- Insider Monkey
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2023 Results Conference Call and Webcast. [Operator Instructions] Please note, today’s call is being recorded. I would now like to turn the conference call over to the company. Please go ahead. Grace […]
